The Overview
Cerevance announced positive topline results from its randomized, double-blind, placebo-controlled Phase 3 ARISE trial of once-daily oral solengepras as an adjunctive treatment for people with Parkinson's disease experiencing motor fluctuations. Solengepras 150 mg met the primary endpoint, achieving a statistically significant reduction of 0.61 hours in average daily OFF time versus placebo at Week 12 (p=0.0350). The drug also demonstrated statistically significant improvements in key secondary endpoints, including increased ON time without troublesome dyskinesia by 0.60 hours (p=0.0468) and improved motor experiences of daily living (MDS-UPDRS Part II) by 1.91 points (p=0.0008). Solengepras was generally well tolerated, with a discontinuation rate similar to placebo. Cerevance plans to meet with the FDA to discuss the path to a potential New Drug Application.
Knolens Analysis
At a Glance
| Indication | Parkinson's disease |
| Drug | Solengepras |
| Mechanism of Action | GPR6 inhibitor |
| Company | Cerevance |
| Trial Phase | Phase 3 |
| Trial Acronym | ARISE |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Neuroscience |
| Primary Endpoint Result | 0.61 hours reduction in average daily OFF time vs. placebo at Week 12 (p=0.0350) |
| Key Secondary Endpoint Result | 0.60 hours increase in ON time without troublesome dyskinesia vs. placebo (p=0.0468) |
| Patient Population Size | 341 participants |
| Dosage Regimen | 150 mg once-daily oral |
| Comparator | Placebo |
| Trial Duration | 12 weeks |
| Regulatory Plan | Meeting with FDA to discuss New Drug Application |
| Presentation Venue | 2026 International Congress of Parkinson's Disease and Movement Disorders (MDS), Seoul, Korea |
| Patient Characteristics | Parkinson's disease patients with motor fluctuations on levodopa and other Parkinson’s medications, with ≥3 hours daily OFF time |
| Adverse Event Discontinuation Rate | 3.5% across all arms, including placebo |
Cerevance's Solengepras Achieves Primary Endpoint in Phase 3 ARISE Trial
Cerevance announced positive topline results from its randomized, double-blind, placebo-controlled Phase 3 ARISE trial of once-daily oral solengepras as an adjunctive treatment for people with Parkinson's disease experiencing motor fluctuations. Solengepras 150 mg met the primary endpoint, achieving a statistically significant reduction of 0.61 hours in average daily OFF time versus placebo at Week 12 (p=0.0350). The drug also demonstrated statistically significant improvements in key secondary endpoints, including increased ON time without troublesome dyskinesia by 0.60 hours (p=0.0468) and improved motor experiences of daily living (MDS-UPDRS Part II) by 1.91 points (p=0.0008). Solengepras was generally well tolerated, with a discontinuation rate similar to placebo. Cerevance plans to meet with the FDA to discuss the path to a potential New Drug Application.
- Solengepras 150 mg successfully met its primary endpoint in the ARISE trial, demonstrating a statistically significant reduction of 0.61 hours in average daily OFF time compared to placebo at Week 12 (p=0.0350). This significant benefit was observed as early as Week 2, the first post-baseline assessment, and was consistently maintained throughout the 12-week study period.
- The trial also showed broad benefits across key secondary endpoints, with solengepras 150 mg increasing ON time without troublesome dyskinesia by 0.60 hours (p=0.0468) and improving motor experiences of daily living (MDS-UPDRS Part II) by 1.91 points (p=0.0008). Additionally, exploratory measures indicated improvements in daytime sleepiness (Epworth Sleepiness Scale) and overall quality of life (PDQ-39).
- Solengepras was generally well tolerated, with most adverse events being mild or moderate. The discontinuation rate due to adverse events was low at 3.5% across all three arms, including placebo. The adverse event profile, which showed fewer typical dopaminergic side effects like dyskinesia (4.4% vs 1.8% placebo), is consistent with its novel non-dopaminergic mechanism of action.
Frequently Asked Questions
What is the most recently developed treatment for Parkinson's disease?
The most recently developed treatment for Parkinson's disease is IPX203, an extended-release carbidopa/levodopa formulation approved by the FDA in June 2023. This oral capsule is designed to provide more consistent levodopa plasma concentrations, aiming to reduce "off" time and improve motor fluctuations in patients. It offers a new option for managing the motor symptoms of Parkinson's disease.
What are some self-care strategies for people with Parkinson's disease?
Self-care strategies for Parkinson's disease patients primarily involve consistent physical activity, such as aerobic exercise, strength training, and balance exercises, to maintain mobility and mitigate motor symptoms. A balanced, nutrient-rich diet, adequate hydration, and optimized sleep hygiene are crucial for overall well-being and managing non-motor symptoms. Furthermore, stress reduction techniques, cognitive engagement, and strict adherence to prescribed pharmacotherapy regimens are essential for symptom management and improving quality of life.
What are five signs that someone might be developing Parkinson's disease?
Five signs indicating potential Parkinson's disease development include resting tremor, bradykinesia, rigidity, and postural instability. Additionally, non-motor symptoms such as olfactory dysfunction, often preceding motor onset, are significant early indicators.
What are the symptoms of advanced Parkinson's disease?
Advanced Parkinson's disease is characterized by a significant progression of both motor and non-motor symptoms, often leading to severe disability and reduced quality of life. Motor complications include debilitating dyskinesia, prolonged "off" periods, severe gait disturbances, and frequent falls due to postural instability. Non-motor symptoms become more prominent and challenging, encompassing cognitive impairment (dementia), psychosis, severe autonomic dysfunction (e.g., orthostatic hypotension, dysphagia), and intractable sleep disorders. These combined symptoms often necessitate advanced therapeutic interventions and increased caregiver support.
What is the standard of care for Parkinson's?
Levodopa, typically combined with carbidopa, remains the most effective symptomatic treatment and the cornerstone of pharmacological management for Parkinson's disease. Dopamine agonists, MAO-B inhibitors, and COMT inhibitors are also widely used, often as initial monotherapy or adjuncts to manage motor symptoms. For advanced disease with motor fluctuations, deep brain stimulation (DBS), levodopa-carbidopa intestinal gel (LCIG), and subcutaneous apomorphine are established options. Comprehensive care also includes physical, occupational, and speech therapy to address motor and non-motor symptoms.
What is the 5:2:1 rule for Parkinson's?
The 5:2:1 rule for Parkinson's describes a common scenario in advanced disease where patients take levodopa 5 times a day, with doses spaced 2 hours apart, yet only experience approximately 1 hour of "good ON" time per dose. This illustrates the challenge of motor fluctuations and the diminishing efficacy of individual levodopa doses over time, highlighting the need for optimized dosing strategies or advanced therapies to maintain stable levodopa plasma levels.
What is the gold standard treatment for Parkinson's disease?
Levodopa remains the gold standard treatment for Parkinson's disease, offering the most effective symptomatic relief for motor symptoms such as bradykinesia and rigidity. It acts as a dopamine precursor, replenishing dopamine levels in the brain. While highly efficacious, its long-term use is associated with motor complications like dyskinesias and "wearing-off" periods, often requiring careful dose titration and adjunctive therapies.
What kind of care does a person with Parkinson's need?
Parkinson's disease care necessitates a comprehensive, multidisciplinary approach addressing both motor and non-motor symptoms. This involves pharmacological management by a neurologist or movement disorder specialist, complemented by physical, occupational, and speech therapies to maintain function and mitigate symptom progression. Care also extends to managing non-motor symptoms such as cognitive changes, mood disorders, and autonomic dysfunction, often requiring input from mental health professionals and other specialists. As a progressive condition, care plans must be dynamic, adapting to evolving patient needs and disease stage.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
